Uninterrupted versus interrupted direct oral anticoagulation for catheter ablation of atrial fibrillation: A systematic review and meta-analysis

被引:7
作者
Asad, Zain Ul Abideen [1 ]
Akhtar, Khawaja H. [1 ]
Jafry, Ali H. [1 ]
Khan, Muhammad Haris [2 ]
Khan, Muhammad Shahzeb [3 ]
Munir, Muhammad Bilal [4 ]
Lakkireddy, Dhanunjaya R. [5 ]
Gopinathannair, Rakesh [5 ]
机构
[1] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA
[2] Nishtar Med Coll, Dept Internal Med, Multan, Pakistan
[3] John H Stroger Jr Hosp Cook Country, Dept Internal Med, Chicago, IL USA
[4] Univ Calif San Diego, Div Cardiol, Sect Electrophysiol, La Jolla, CA 92093 USA
[5] Kansas City Heart Rhythm Inst, Electrophysiol Sect, Overland Pk, KS USA
关键词
atrial fibrillation; catheter ablation; direct‐ acting oral anticoagulants; meta‐ analysis; systematic review; COMPLICATIONS; RIVAROXABAN; DABIGATRAN; APIXABAN; EFFICACY; SAFETY;
D O I
10.1111/jce.15043
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction To evaluate the safety of uninterrupted versus interrupted direct oral anticoagulation (DOAC) for patients undergoing catheter ablation (CA) of atrial fibrillation (AF). Methods We conducted a systematic search of MEDLINE and EMBASE for randomized controlled trials (RCT) and observational studies comparing uninterrupted versus interrupted DOAC for patients undergoing CA of AF. Primary outcome was major bleeding. Secondary outcomes included minor bleeding, stroke or transient ischemic attack (TIA) or thromboembolism (TE), silent cerebral ischemic events, and cardiac tamponade. Meta-analysis was stratified by study design. Risk ratios (RR) with 95% confidence intervals were calculated using random effects model and Mantel-Haenszel method was used to pool RR. Results A total of 13 studies (7 randomized, 6 observational) comprising 3595 patients were included. The RCT restricted analysis did not show any difference in terms of major bleeding (risk ratio [RR] = 0.79; [0.35-1.79]), minor bleeding (RR = 0.99 [0.68-1.43]), stroke or TIA or TE (RR = 0.80 [0.19-3.32]), silent cerebral ischemic events (RR = 0.64 [0.32-1.28]), and cardiac tamponade (RR = 0.61 [0.20-1.92]). Observational study restricted analysis showed a protective effect of uninterrupted DOAC on silent cerebral ischemic events (RR = 0.45 [0.31-0.67]) and no difference in other outcomes. Conclusions There is no difference in bleeding and thromboembolic outcomes with uninterrupted versus interrupted DOAC for CA of AF and observational data suggests that uninterrupted DOACs are protective against silent cerebral ischemic lesions.
引用
收藏
页码:1995 / 2004
页数:10
相关论文
共 33 条
[1]  
Ando M, 2019, HEART VESSELS, V34, P1533, DOI 10.1007/s00380-019-01370-9
[2]  
[Anonymous], Covidence systematic review software
[3]   Feasibility of Uninterrupted Direct Oral Anticoagulants with Temporary Switching to Dabigatran ("Dabigatran Bridge") for Catheter Ablation of Atrial Fibrillation [J].
Aoyama, Daisetsu ;
Miyazaki, Shinsuke ;
Hasegawa, Kanae ;
Kaseno, Kenichi ;
Ishikawa, Eri ;
Mukai, Moe ;
Miyahara, Kosuke ;
Aiki, Takayoshi ;
Matsui, Akira ;
Yamaguchi, Junya ;
Shiomi, Yuichiro ;
Tama, Naoto ;
Ikeda, Hiroyuki ;
Fukuoka, Yoshitomo ;
Morishita, Tetsuji ;
Ishida, Kentaro ;
Uzui, Hiroyasu ;
Tada, Hiroshi .
INTERNATIONAL HEART JOURNAL, 2019, 60 (06) :1315-1320
[4]   Early vs Late Discharge in Low-Risk ST-Elevation Myocardial Infarction Patients TreatedWith Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis [J].
Asad, Zain Ul Abideen ;
Khan, Safi U. ;
Amritphale, Amod ;
Shroff, Adhir ;
Lata, Kusum ;
Seto, Arnold H. ;
Khan, Muhammad Shahzeb ;
Rao, Sunil, V ;
Abu-Fadel, Mazen .
CARDIOVASCULAR REVASCULARIZATION MEDICINE, 2020, 21 (11) :1360-1368
[5]   Catheter Ablation Versus Medical Therapy for Atrial Fibrillation A Systematic Review and Meta-Analysis of Randomized Controlled Trials [J].
Asad, Zain Ul Abideen ;
Yousif, Ali ;
Khan, Muhammad Shahzeb ;
Al-Khatib, Sana M. ;
Stavrakis, Stavros .
CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY, 2019, 12 (09)
[6]  
Calkins H, 2018, EUROPACE, V20, P157, DOI [10.1093/europace/eux275, 10.1093/europace/eux274, 10.1016/j.hrthm.2017.05.012]
[7]   Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation [J].
Calkins, Hugh ;
Willems, Stephan ;
Gerstenfeld, Edward P. ;
Verma, Atul ;
Schilling, Richard ;
Hohnloser, Stefan H. ;
Okumura, Ken ;
Serota, Harvey ;
Nordaby, Matias ;
Guiver, Kelly ;
Biss, Branislav ;
Brouwer, Marc A. ;
Grimaldi, Massimo .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (17) :1627-1636
[8]   Outcomes after catheter ablation and cardioversion in patients with non-valvular atrial fibrillation: results from the prospective, observational XANTUS study [J].
Camm, A. John ;
Turpie, Alexander G. G. ;
Hess, Susanne ;
Amarenco, Pierre ;
Lambelet, Marc ;
Haas, Sylvia ;
van Eickels, Martin ;
Kirchhof, Paulus .
EUROPACE, 2018, 20 (06) :E87-E95
[9]   Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation [J].
Cappato, Riccardo ;
Marchlinski, Francis E. ;
Hohnloser, Stefan H. ;
Naccarelli, Gerald V. ;
Xiang, Jim ;
Wilber, David J. ;
Ma, Chang-Sheng ;
Hess, Susanne ;
Wells, Darryl S. ;
Juang, George ;
Vijgen, Johan ;
Huegl, Burkhard J. ;
Balasubramaniam, Richard ;
De Chillou, Christian ;
Davies, D. Wyn ;
Fields, L. Eugene ;
Natale, Andrea .
EUROPEAN HEART JOURNAL, 2015, 36 (28) :1805-1811
[10]   Random-effects model for meta-analysis of clinical trials: An update [J].
DerSimonian, Rebecca ;
Kacker, Raghu .
CONTEMPORARY CLINICAL TRIALS, 2007, 28 (02) :105-114